← Back to Search

Hypnotic

Medications for PTSD-Related Insomnia (NAP Trial)

Phase 3
Recruiting
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Females of childbearing potential must agree not to become pregnant or breastfeed during the course of the study
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

NAP Trial Summary

This trial is testing if taking medications for insomnia can help decrease symptoms of PTSD.

Who is the study for?
This trial is for veterans aged 18-75 with PTSD-related insomnia, who have a significant level of sleep disturbance and PTSD symptoms. Participants must be able to give informed consent, adhere to lifestyle guidelines, and allow phone interview recordings. They should not have severe medical conditions or substance dependence, nor be involved in other clinical studies.Check my eligibility
What is being tested?
The study tests if trazodone, eszopiclone, or gabapentin can improve sleep for those with PTSD-related insomnia. It's a comparison against a placebo over approximately 17 weeks. Patients are randomly assigned to one of the medications or placebo without knowing which they receive.See study design
What are the potential side effects?
Potential side effects may include drowsiness, dizziness, nausea, headache and sometimes more complex sleep behaviors like sleepwalking. Each medication has its own profile of possible side effects that participants will be monitored for throughout the trial.

NAP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I agree not to become pregnant or breastfeed during the study.

NAP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Insomnia Severity Index
Secondary outcome measures
Clinician Administered PTSD Scale for DSM-5
Generalized Anxiety Disorder-7 Scale
PTSD Checklist
+5 more

NAP Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: TrazodoneActive Control1 Intervention
Participants who are assigned to take trazodone, an active study medication.
Group II: EszopicloneActive Control1 Intervention
Participants who are assigned to take eszopiclone, an active study medication.
Group III: PlaceboPlacebo Group1 Intervention
Participants who are assigned to take a placebo, a non-active study medication.

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,622 Previous Clinical Trials
3,322,943 Total Patients Enrolled
26 Trials studying Insomnia
3,423 Patients Enrolled for Insomnia
John H. Krystal, MDStudy ChairVA Connecticut Healthcare System West Haven Campus, West Haven, CT
1 Previous Clinical Trials
163 Total Patients Enrolled

Media Library

Eszopiclone (Hypnotic) Clinical Trial Eligibility Overview. Trial Name: NCT03668041 — Phase 3
Insomnia Research Study Groups: Trazodone, Eszopiclone, Placebo
Insomnia Clinical Trial 2023: Eszopiclone Highlights & Side Effects. Trial Name: NCT03668041 — Phase 3
Eszopiclone (Hypnotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03668041 — Phase 3
Insomnia Patient Testimony for trial: Trial Name: NCT03668041 — Phase 3
~258 spots leftby Feb 2026